• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Vinod Babu Damodaran - Articles and news items

Preparing biocompatible materials for non-permanent medical devices

Issue 5 2012, Polymers / 22 October 2012 / Vinod B. Damodaran and Jessica M. Joslin, Department of Chemistry, Colorado State University and Melissa M. Reynolds, Department of Chemistry and School of Biomedical Engineering, Colorado State University

Biodegradable polymers comprise an important class of biomaterials due to their ability to satisfy short-term requirements for medical applications where a permanent implant is not required. However, current biodegradable polymers suffer from undesirable chemical properties that lead to improper elimination from the body and potentially toxic by-products. Additionally, medical polymers cause adverse biological responses at the material-body interface and therefore require some functionality to regulate such processes. To overcome problems such as processability and solubility issues, we describe our approach to synthesising new classes of biodegradable polymers with desirable structural features that exhibit good solubility, tunable degradation and non-toxic by-products. Additionally, these polymers are functionalised for release of the therapeutic agent, nitric oxide (NO), which serves to regulate initial and long-term biological responses.

Two different classes of modified polymer are presented; the first is based on poly(lactic-coglycolic acid) (PLGH) and the second on dextran. We present the NO release profiles associated with several polymer derivatives of both classes along with their degradation timelines. Overall, the PLGH derivatives are processable as films or fibres and show promise in wound healing and tissue engineering applications while the dextran materials are feasible as prodrugs in the cardiovascular system.

Figure 1 for Proteomics

Protein PEGylation: An overview of chemistry and process considerations

Issue 1 2010, Proteomics / 22 February 2010 /

Innovative drug delivery technologies are key components of drug development, with commercial and intellectual values. PEGylation is an excellent example of a delivery system that has scientific and multi- billion dollar commercial importance due to the remarkable improvement in the circulatory half lives of therapeutics, especially for proteins and peptides but even for small molecule pharmaceuticals. Beginning with a brief introduction to the pharmaceutical advantages of PEGylated therapeutics, the authors review the development of this technology over the past four decades in terms of conjugation chemistry, poly(ethylene glycol) structure and process considerations, and conclude that improved, versatile and generic production methods are required to meet the growing demands of the pharmaceutical market…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +